Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium
December 11, 2024 07:05 ET | Source: Celcuity Inc. Median overall survival…
IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001
Based on more than six months of additional monitoring, data show continued…
Investigational Epcoritamab (DuoBody CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
Media ReleaseCOPENHAGEN, Denmark; December 8, 2024 Preliminary analyses from the EPCORE® CLL-1…
Combination of Eflornithine and Lomustine Demonstrates Clinically Meaningful Improvements in Overall Survival (OS) and Progression Free Survival (PFS) in Patients with Recurrent Astrocytoma, IDH Mutant Grade 3
November 22, 2024 11:00 ET | Source: Orbus Therapeutics, Inc. – OS…
Cytek Biosciences Named Overall BioTech Company of the Year in 2024 BioTech Breakthrough Awards Program
FREMONT, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq:…
HPL Electric & Power Ltd. Reports Strong Q2 & H1 FY25 Results with 114.98% YoY PAT Surge for H1; Overall Growth of 21.46%
Order Book exceeding ₹3,500+ Crore by the end of H1 NEW DELHI,…
HPL Electric & Power Ltd. Reports Strong Q2 & H1 FY25 Results with 114.98% YoY PAT Surge for H1; Overall Growth of 21.46%
Order Book exceeding ₹3,500+ Crore by the end of H1 NEW DELHI,…
HPL Electric & Power Ltd. Reports Strong Q2 & H1 FY25 Results with 114.98% YoY PAT Surge for H1; Overall Growth of 21.46%
Order Book exceeding ₹3,500+ Crore by the end of H1 NEW DELHI,…
HPL Electric & Power Ltd. Reports Strong Q2 & H1 FY25 Results with 114.98% YoY PAT Surge for H1; Overall Growth of 21.46%
Order Book exceeding ₹3,500+ Crore by the end of H1 NEW DELHI,…
HPL Electric & Power Ltd. Reports Strong Q2 & H1 FY25 Results with 114.98% YoY PAT Surge for H1; Overall Growth of 21.46%
Order Book exceeding ₹3,500+ Crore by the end of H1 NEW DELHI,…